KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

Research output: Contribution to journalReview articlepeer-review

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume78
Issue number2
DOIs
StatePublished - 25 Aug 2021

Keywords

  • COVID-19
  • Disease management
  • Inflammatory bowel diseases
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement'. Together they form a unique fingerprint.

Cite this